Regeneron Pharmaceuticals (REGN) Receiving Somewhat Favorable Media Coverage, Study Finds
News articles about Regeneron Pharmaceuticals (NASDAQ:REGN) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.3074804445183 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Regeneron Pharmaceuticals, Inc. (REGN) Now Covered by Analysts at Royal Bank Of Canada (americanbankingnews.com)
- REGENERON PHARMACEUTICALS,INC. (NASDAQ:REGN) Files An 8-K Submission of Matters to a Vote of Security Holders (4-traders.com)
- Regeneron’s Delivery Isn’t Matching the Hype (finance.yahoo.com)
- Oversold Conditions For Regeneron Pharmaceuticals (REGN) – Nasdaq (nasdaq.com)
- Regeneron’s Frustrating Month: Analysis And Commentary – Seeking Alpha (seekingalpha.com)
Several equities analysts have recently weighed in on REGN shares. Canaccord Genuity set a $484.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 20th. BTIG Research reissued a “buy” rating and set a $540.00 price target (up from $480.00) on shares of Regeneron Pharmaceuticals in a report on Friday, June 30th. BidaskClub cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Bank of America Corporation reissued a “buy” rating and set a $593.00 price target (up from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Citigroup Inc. increased their price target on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $496.35.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded up 0.81% on Thursday, hitting $441.30. 987,656 shares of the company were exchanged. The firm’s 50-day moving average is $474.95 and its 200-day moving average is $444.94. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The stock has a market capitalization of $46.79 billion, a PE ratio of 44.27 and a beta of 1.65.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.82 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current year.
In related news, EVP Robert J. Terifay sold 21,147 shares of the company’s stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $468.19, for a total transaction of $9,900,813.93. Following the completion of the sale, the executive vice president now owns 72,043 shares of the company’s stock, valued at approximately $33,729,812.17. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert E. Landry sold 189 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the sale, the chief financial officer now directly owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 120,690 shares of company stock valued at $57,732,183. 10.40% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals (REGN) Receiving Somewhat Favorable Media Coverage, Study Finds” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/regeneron-pharmaceuticals-regn-receiving-somewhat-favorable-media-coverage-study-finds/1562519.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.